391-12-8

Basic information

• Product Name: 7-(Trifluoromethyl)indoline-2,3-dione
• Synonyms: BUTTPARK 24\07-40;7-(TRIFLUOROMETHYL)INDOLINE-2,3-DIONE;7-(TRIFLUOROMETHYL)ISATIN;7-(TRIFLUOROMETHYL)-1H-INDOLE-2,3-DIONE;7-(trifluoromethyl)indole-2,3-dione;7-(Trifluoromethyl)indoline-2,3-dione 98%;7-(Trifluoromethyl)indoline-2,3-dione98%;7-TRIFLUOROMETHYLINDOLE
• CAS NO: 391-12-8
• Molecular Formula: C₉H₄F₃NO₂
• Molecular Weight: 215.13
• EINECS: 1312995-182-4
• Product Categories: blocks;IndolesOxindoles;Heterocyclic Compounds;All Inhibitors;Indoles;Simple Indoles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 391-12-8.mol
• Article Data: 18

Chemical Properties

• Melting Point: 192-193
• Appearance: Brown solid
• Density: 1.525 g/cm³
• Refractive Index: 1.513
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 9.43±0.20(Predicted)
• CAS DataBase Reference: 7-(Trifluoromethyl)indoline-2,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(Trifluoromethyl)indoline-2,3-dione(391-12-8)
• EPA Substance Registry System: 7-(Trifluoromethyl)indoline-2,3-dione(391-12-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36-52
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 391-12-8(Hazardous Substances Data)

Usage

Chemical Properties

7-(Trifluoromethyl)indoline-2,3-dione is Brown Solid

Uses

Different sources of media describe the Uses of 391-12-8 differently. You can refer to the following data:
1. 7-(Trifluoromethyl)indoline-2,3-dione is an indole derivative as inhibitor of COX-1, COX-2, and ?catenin.Useful in the treatment of diseases such as: lung cancer, diabetes and Alzheimer disease.
2. An indole derivative as inhibitor of COX-1, COX-2, and β-catenin. Useful in the treatment of diseases such as: lung cancer, diabetes and Alzheimer's disease.
3. An indole derivative as inhibitor of COX-1, COX-2, and β-catenin. Useful in the treatment of diseases such as: lung cancer, diabetes and Alzheimer''s disease.

InChI:InChI=1/C9H4F3NO2/c10-9(11,12)5-3-1-2-4-6(5)13-8(15)7(4)14/h1-3H,(H,13,14,15)

Upstream product

• 88-17-5 2-(trifluoromethyl)benzenamine 
• 444-93-9 (E)-2-(hydroxyimino)-N-(2-(trifluoromethyl)phenyl)acetamide 
• 13061-96-6 dihydroxy-methyl-borane 
• 1067187-88-5 5-iodo-7-(trifluoromethyl)indoline-2,3-dione 
• 444-93-9 2-hydroxyimino-N-(2-trifluoromethyl-phenyl)-acetamide 

Downstream Products

• 1067187-88-5 5-iodo-7-(trifluoromethyl)indoline-2,3-dione 
• 1067186-52-0 3-hydroxy-2-(1-phenylcyclopropyl)-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067187-37-4 3-hydroxy-2-(2-phenylpropan-2-yl)-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067186-56-4 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067186-76-8 2-(1-(4-chlorophenyl)cyclobutyl)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067186-73-5 2-(1-(2-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067187-46-5 3-hydroxy-2-(1-phenylpropyl)-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1239150-04-9 2-[1-(4-chlorophenyl)-2-methylpropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067186-74-6 3-hydroxy-2-(1-(4-(trifluoromethoxy)phenyl)cyclopropyl)-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067186-70-2 3-hydroxy-8-(trifluoromethyl)-2-(1-(4-(trifluoromethyl)phenyl)cyclopropyl)quinoline-4-carboxylic acid 
• 1067186-75-7 3-hydroxy-8-(trifluoromethyl)-2-(1-(3-(trifluoromethyl)phenyl)cyclopropyl)quinoline-4-carboxylic acid 
• 1067186-79-1 2-(1-(4-fluorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1067187-43-2 3-hydroxy-2-(1-phenylethyl)-8-(trifluoromethyl)quinoline-4-carboxylic acid 
• 1394901-87-1 2-(4-methoxyphenyl)-7-trifluoromethylpyrrolo[2,3,4-kl]acridin-1(2H)-one 

Relevant articles and documents

Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof

The invention discloses a benzenesulfonamide compound represented by a general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method and application thereof. Compared with the prior art, the benzenesulfonamide compound disclosed by the invention can be used as an isocitrate dehydrogenase 2 (IDH2) mutant inhibitor. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibiting effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process of catalyzing alpha-ketoglutaricacid to generate 2-hydroxyglutaric acid by mIDH2, and can be used for preventing and/or treating various related diseases including cancers and the like caused by IDH2 mutation.

Ylide mediated carbonyl homologations for the preparation of isatin derivatives

An exceptionally mild method for the preparation of isatin derivatives has been developed using a sulfur ylide mediated carbonyl homologation sequence starting from anthranilic acid precursors. This method proceeds at ambient temperature via a sulfur ylide intermediate without the need for protection of the amine or chromatographic isolation of the intermediate ylide. Gentle oxidation of the sulfur ylides provides isatin derivatives with N-H, N-alkyl, N-aryl substitution, electron-rich and electron-poor aromatic rings, and heterocyclic aromatic systems. We anticipate that this method will greatly expand the accessibility of complex isatin derivatives.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.